This is a Phase 4, observational, open study in patients who their doctor has prescribe METPURE XL (S (-)metoprolol succinate)by clinical practice. No medication was provided by the sponsor. The planned observation time is 8 weeks. The 8 weeks of observation involves an evaluation of baseline followed by information gathered from the assessment visits at week 4 and week 8.
Study Type
OBSERVATIONAL
Enrollment
2,000
Country Club de Bogota
Bogotá, Colombia
Effect of therapy in the management of cardiovascular diseases
The objective is to mesure the effect of Metpure XL in cadiovascular diseases as hypertension, post MI and coronary disease
Time frame: 8 weeks
Evaluate and compare the rate of compliance with treatment
Evaluate the compliance with METPURE XL, to be able to identify possible reasons for noncompliance or quitting the treatment
Time frame: 8 weeks
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
To assess the safety pattern in Colombian subjects using s(-)metoprolol succinate
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.